Ikena Oncology, Inc.

NasdaqGM:IKNA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 65.63 M

Share Price

USD 1.36

Avg Daily Volume

96,401

Change (1 day)

-0.73%

Change (1 year)

-18.07%

Change (YTD)

-17.07%

Ikena Oncology, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025

Ikena Oncology, Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending March 31, 2025. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Ikena Oncology, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -1,937.03%, a 395.08% change year over year.
Ikena Oncology, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -391.26%, a 196.69% change year over year.
Ikena Oncology, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -131.87%, a -73.14% change year over year.
Ikena Oncology, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -491.03%.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA Margin	Net Income Margin	EBT Margin	Operating Income Margin

NasdaqGM: IKNA

Ikena Oncology, Inc.

CEO	Dr. Mark Manfredi Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	645 Summer Street
Employees	10
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.